San Matteo University Report issue

Academic/Hospital Phase 2

Organization Overview

First Clinical Trial
2008
NCT00551252
First Marketed Drug
None
First NDA Approval
None
Last Known Activity
2018

Timeline

NOW
  • Now

Alternative names

Fondazione IRCCS Policlinico S. Matteo - Pavia | Medical Oncology, IRCCS San Matteo University Hospital Foundation, pavia, Italy

Active Ingredients

Drugs in Phase 2 Trials (2)

gemcitabine (gemzar) (1 trial)

imatinib (gleevec) (1 trial)

Indications

Experimental Indications (Clinical Trials, Phases 1-4)


 

Mesothelioma (Phase 2)

Overview

  • Highest Phase: Phase 2
  • # of Trials: 1
  • # of Trial APIs: 2